Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Lance Okeke

HIV/AIDS Medicine · Duke University

View

Dr. Raphael J. Landovitz

HIV/AIDS Medicine · UCLA

View

Dr. Aniruddha Hazra

HIV/AIDS Medicine · UCMC

View

Dr. Shital Patel

HIV/AIDS Medicine · BCM

View

Dr. Monica Gandhi

HIV/AIDS Medicine · UCSF

View

Dr. Ashwin Balagopal

HIV/AIDS Medicine · Johns Hopkins

View

Dr. Ofole Mgbako

HIV/AIDS Medicine · NYU Langone

View

Dr. Joshua Barocas

HIV/AIDS Medicine · CU Anschutz Medical Campus

View

Dr. Chris Beyrer

Global Health · Duke University

View

Dr. Keith Kaye

General ID · RU

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Short Course Therapy With Glecaprevir/Pibrentasvir for Early Hepatitis C Virus Infection: PURGE-C.

    Feb 4, 2026DOI: 10.1093/cid/ciaf305Journal ArticleCID

    Written by: Arthur Y KimMinhee KangTriin UmblejaEstevão P NunesKristen M MarksAnne F LuetkemeyerCarrington KoebeleChanelle WimbishDaniel S FiererDimas A KliemannSunil S SolomonJens KortJennifer J KiserGeorg M LauerRaymond T ChungLeonard A SowahBeverly L Alston-SmithDavid L WylesSusanna NaggieA5380 Study Team

    Find these authors on Roon

    AK

    Dr. Arthur Kim

    HIV/AIDS Medicine · MGH

    SS

    Dr. Sunil Solomon

    HIV/AIDS Medicine

    Summary

    BACKGROUND: Shorter treatment courses for early hepatitis C virus (HCV) infection could simplify treatment approaches, particularly in key populations.METHODS: PURGE-C (A5380) was a single-arm, multicenter trial evaluating the treatment of early HCV (primary or reinfection) with 4 weeks of glecaprevir/pibrentasvir (G/P). Early HCV was defined as new detectable HCV RNA or alanine aminotransferase (ALT) elevation within 24 weeks of study entry. The primary endpoint was sustained virologic response (SVR) 12 weeks after prescribed treatment completion (SVR12). Re-treatment outcomes were also collected.RESULTS: Forty-five participants (98% male, 51% White, 31% Hispanic, median age 36 years, 51% with human immunodeficiency virus [HIV], 27% self-reported injecting drugs) were enrolled from the United States and Brazil between November 2019 and January 2023. Median time from HCV diagnosis to entry was 31 days (Q1-Q3: 15-49). Median baseline HCV RNA was 5.3 log10 IU/mL (Q1-Q3: 3.3-6.0) and ALT 146 U/L (min-max: 22-3866). Overall, 38 of 45 (84%) participants (90% confidence interval achieved SVR12. All 4 participants who were retreated and had outcome data achieved SVR12.CONCLUSIONS: In this population with elevated risk of onward HCV transmission, 84% were cured with 4 weeks of G/P. Failing this short-course treatment did not compromise retreatment. This study suggests that people with early HCV infection can achieve moderately high cure rates with abbreviated courses of direct-acting antivirals (DAA). Simplified approaches to treatment are critical for HCV elimination and are particularly relevant for populations difficult to retain in care.CLINICAL TRIAL REGISTRATION: NCT04042740.
    RBDr. Rachel Bender Ignacio

    Dr. Rachel Bender Ignacio

    Infectious Disease · HIV & AIDS Medicine
    Fred Hutchinson/University of Washington/Seattle Children’s Cancer Consortium
    rachelb